title: Comparative effect of carperitide and furosemide on left atrial pressure in dogs with experimentally induced mitral valve regurgitation.
abstract: BACKGROUND
  The effects of carperitide on left atrial pressure (LAP) in dogs with mitral valve disease (mitral regurgitation, MR) have not been documented.
  
  
  OBJECTIVE
  The objective was to compare the short-term effects of carperitide versus furosemide on LAP and neurohumoral factors in MR dogs.
  
  
  METHODS
  Six healthy Beagle dogs weighing 9.8-12.6 kg (2 males and 4 females; aged 3 years) were used.
  
  
  METHODS
  Experimental, randomized, cross-over, and interventional study. Carperitide 0.1 μg/kg/min or furosemide 0.17 mg/kg/h (1 mg/kg/6 h) was administered to dogs with surgically induced MR for 6 hours, and after a 14 day wash-out period, the other drug was administered. LAP, plasma renin activity, plasma aldosterone, and echocardiographic variables were measured.
  
  
  RESULTS
  Left atrial pressure was decreased similarly after the administration of carperitide 0.1 μg/kg/min and furosemide 0.17 mg/kg/h (1 mg/kg/6 h) compared with baseline in dogs with MR (Baseline 14.75 ± 3.74 mmHg, carperitide 10.24 ± 4.97 mmHg, P < .01, furosemide 10.77 ± 5.06 mmHg, P < .05). Plasma renin activity and plasma aldosterone were significantly lower after the administration of carperitide than after the administration of furosemide (P < .05, respectively).
  
  
  CONCLUSIONS
  Carperitide significantly decreased LAP in dogs with acute MR caused by experimental chordal rupture. Carperitide can have additional benefits from the viewpoint of minimal activation of neurohumoral factors in the treatment of dogs with MR. Additional studies in dogs with spontaneous disease are warranted.
authors: Department of Veterinary Surgery, Faculty of Veterinary Medicine, Tokyo University of Agriculture and Technology, Fuchu-shi, Tokyo, Japan.
authors: S
authors: S
authors: Suzuki
authors: R
authors: R
authors: Fukushima
authors: Y
authors: Y
authors: Yamamoto
authors: T
authors: T
authors: Ishikawa
authors: L
authors: L
authors: Hamabe
authors: S
authors: S
authors: Kim
authors: R
authors: R
authors: Yoshiyuki
authors: T
authors: T
authors: Fukayama
authors: N
authors: N
authors: Machida
authors: R
authors: R
authors: Tanaka
mesh_terms: D000818:Animals; D009320:Atrial Natriuretic Factor / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D018592:Cross-Over Studies; D004283:Dog Diseases / Q000188:drug therapy* / Q000209:etiology; D004285:Dogs; D004452:Echocardiography; D005260:Female; D005665:Furosemide / Q000627:therapeutic use*; D006728:Hormones / Q000097:blood; D008297:Male; D008944:Mitral Valve Insufficiency / Q000188:drug therapy* / Q000209:etiology; D008991:Monitoring, Physiologic / Q000295:instrumentation / Q000379:methods / Q000662:veterinary
chemical_list: D006728:Hormones; C472955:NPPA protein, human; D005665:Furosemide; D009320:Atrial Natriuretic Factor
keywords: Atrial natriuretic peptide; Carperitide; Mitral valve disease